HCV
MCID: HPT073
MIFTS: 71

Hepatitis C Virus (HCV)

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Mental diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Hepatitis C Virus

MalaCards integrated aliases for Hepatitis C Virus:

Name: Hepatitis C Virus 57
Hepatitis C Virus Infection, Response to Therapy of 57 29 6
Susceptibility to Hepatitis C Virus 29 6
Hepatitis C Virus, Response to Therapy of 57
Virus, Hepatitis C, Susceptibility to 39
Hepatitis C Virus, Susceptibility to 57
Hepatitis C Virus, Resistance to 57
Resistance to Hepatitis C Virus 6
Hcv, Susceptibility to 57
Hcv 57

Classifications:



External Ids:

OMIM® 57 609532

Summaries for Hepatitis C Virus

OMIM® : 57 HCV, which is principally transmitted by blood, infects about 3% of the world's population. HCV infection causes acute hepatitis, which is self-resolving in 20 to 50% of cases but does not confer permanent immunity. In 50 to 80% of cases, HCV infection becomes chronic and results in chronic hepatitis, cirrhosis, and hepatocellular carcinoma. As a result, HCV infection is a leading killer worldwide and the most common cause of liver failure in the U.S. HCV is opportunistic in individuals infected with human immunodeficiency virus (HIV; see 609423), approximately 25% of whom are coinfected with HCV. HCV infection is also associated with cryoglobulinemia (see 123550), a B-lymphocyte proliferative disorder (Pawlotsky, 2004; Chisari (2005); Pileri et al., 1998). (609532) (Updated 05-Apr-2021)

MalaCards based summary : Hepatitis C Virus, also known as hepatitis c virus infection, response to therapy of, is related to hepatitis c and hepatitis. An important gene associated with Hepatitis C Virus is IFNG (Interferon Gamma), and among its related pathways/superpathways is Toll-like Receptor Signaling Pathway. The drugs Dopamine and Amantadine have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and t cells, and related phenotypes are Increased JFH-1 genotype 2a Hepatitis C virus (HCV) infection and digestive/alimentary

Wikipedia : 73 The hepatitis C virus (HCV) is a small (55-65 nm in size), enveloped, positive-sense single-stranded RNA... more...

Related Diseases for Hepatitis C Virus

Diseases in the Hepatitis family:

Hepatitis C Virus Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis B Hepatitis D
Autoimmune Hepatitis Hepatitis E
Autoimmune Hepatitis Type 2 Autoimmune Hepatitis Type 1

Diseases related to Hepatitis C Virus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1081)
# Related Disease Score Top Affiliating Genes
1 hepatitis c 33.3 SCARB1 PI4KA KRT8 KRT18 IFNL4 IFNG
2 hepatitis 32.9 SCARB1 PSMA7 PI4KA KRT8 KRT18 IFNL4
3 viral hepatitis 32.4 KRT8 KRT18 IFNL3 IFNG
4 immune deficiency disease 32.1 PTPRC IFNG EIF2AK2 CLEC4M CCR5
5 viral infectious disease 32.0 IFNG EIF2AK2 CLEC4M CCR5
6 autoimmune hepatitis 31.6 PTPRC KRT8 KRT18
7 disease by infectious agent 31.5 PTPRC IFNG CLEC4M CCR5
8 acquired immunodeficiency syndrome 31.5 IFNG CCR5 APOE
9 human immunodeficiency virus infectious disease 31.4 PTPRC IFNG CLEC4M CCR5
10 cryptogenic cirrhosis 31.3 KRT8 KRT18
11 human immunodeficiency virus type 1 31.2 IFNG CLEC4M CCR5AS CCR5
12 herpes zoster 30.9 IFNG CCR5 APOE
13 encephalitis 30.8 PTPRC DDX3X CLEC4M CCR5
14 west nile virus 30.7 CLEC4M CCR5AS CCR5
15 west nile encephalitis 30.5 CLEC4M CCR5
16 sarcoidosis 1 30.4 PTPRC IFNG CCR5
17 west nile fever 30.4 CLEC4M CCR5
18 t-cell non-hodgkin lymphoma 30.2 PTPRC CCR5
19 chronic graft versus host disease 30.1 IFNG CCR5
20 multiple sclerosis 29.5 PTPRC IFNG CCR5AS CCR5 APOE
21 hepatocellular carcinoma 11.6
22 cryoglobulinemia, familial mixed 11.5
23 liver cirrhosis 11.5
24 lichen planus 11.4
25 liver disease 11.3
26 polyarteritis nodosa 11.3
27 recurrent hepatitis c virus induced liver disease in liver transplant recipients 11.3
28 hepatitis b 11.3
29 cryoglobulinemia 11.3
30 immunotactoid glomerulopathy 11.2
31 non-alcoholic fatty liver disease 11.2
32 fibrillary glomerulonephritis 11.2
33 gianotti crosti syndrome 11.2
34 immunotactoid or fibrillary glomerulopathy 11.2
35 vasculitis 11.1
36 glomerulonephritis 11.1
37 fibrosis of extraocular muscles, congenital, 1 11.1
38 lymphoma 11.0
39 end stage renal disease 11.0
40 fatty liver disease, nonalcoholic 1 11.0
41 hepatitis a 11.0
42 membranoproliferative glomerulonephritis 11.0
43 b-cell lymphoma 10.9
44 vaccinia 10.9
45 purpura 10.9
46 porphyria 10.9
47 porphyria cutanea tarda 10.9
48 hemophilia 10.9
49 kidney disease 10.9
50 alcohol use disorder 10.9

Graphical network of the top 20 diseases related to Hepatitis C Virus:



Diseases related to Hepatitis C Virus

Symptoms & Phenotypes for Hepatitis C Virus

Clinical features from OMIM®:

609532 (Updated 05-Apr-2021)

GenomeRNAi Phenotypes related to Hepatitis C Virus according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased JFH-1 genotype 2a Hepatitis C virus (HCV) infection GR00233-A-1 8.32 HM13

MGI Mouse Phenotypes related to Hepatitis C Virus:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.7 APOE CCR5 HM13 IFNG KRT8 PI4KA
2 liver/biliary system MP:0005370 9.56 APOE CCR5 HM13 IFNG KRT18 KRT8
3 mortality/aging MP:0010768 9.44 APOE CCR5 CLDN6 CLEC4M DDX3X EIF2AK2

Drugs & Therapeutics for Hepatitis C Virus

Drugs for Hepatitis C Virus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 256)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
2
Amantadine Approved Phase 4 768-94-5 2130
3
Ezetimibe Approved Phase 4 163222-33-1 150311
4
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
5
Metformin Approved Phase 4 657-24-9 4091 14219
6
Iron Approved Phase 4 7439-89-6 23925 29936
7
Simeprevir Approved Phase 4 923604-59-5 66576988
8
Colchicine Approved Phase 4 64-86-8 6167 2833
9
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643 439492
10
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
11
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
12
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
13
Mycophenolic acid Approved Phase 4 24280-93-1 446541
14
Didanosine Approved Phase 4 69655-05-6 50599
15
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
16
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
17
tannic acid Approved Phase 4 1401-55-4
18
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
19
Fosamprenavir Approved Phase 4 226700-79-4 131536
20
Nelfinavir Approved Phase 4 159989-64-7 64143
21
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
22
Zidovudine Approved Phase 4 30516-87-1 35370
23
Cobicistat Approved Phase 4 1004316-88-4
24
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
25
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
26
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
27
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
28
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
29
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
30
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
31
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
32
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
33 Neurotransmitter Agents Phase 4
34 Antiparkinson Agents Phase 4
35 Protective Agents Phase 4
36 Antioxidants Phase 4
37 Anticholesteremic Agents Phase 4
38 Lipid Regulating Agents Phase 4
39 Hypolipidemic Agents Phase 4
40 Opiate Alkaloids Phase 4
41 Platelet Aggregation Inhibitors Phase 4
42
Heroin Phase 4 5462328
43 Detox adjuvant Phase 4
44 Dopamine Agents Phase 4
45 Vasodilator Agents Phase 4
46 Radiation-Protective Agents Phase 4
47 Phosphodiesterase Inhibitors Phase 4
48 Immunologic Factors Phase 4
49 Reverse Transcriptase Inhibitors Phase 4
50 Hypoglycemic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 644)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Daclatasvir Plus Asunaprevir Treatment in Patients With Chronic Hepatitis C : Prospective Cohort Study Unknown status NCT02639585 Phase 4 Daclinza and Sunvepra
2 An Open-Label Study to Evaluate Long-Term Outcomes With Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Fertile Women With Genotype 1 and 4 Chronic Hepatitis C Virus (HCV) Infection Unknown status NCT02950870 Phase 4 Ombitasvir-Paritaprevir-Ritonavir;Dasabuvir;Ribavirin
3 Hepatitis C in Renal Transplant Recipients - Safety and Efficacy of a Conversion of Immunosuppression to High-dose Cyclosporine A and Its Impact on Hepatitis C Virus-replication, Parameters of Liver Function and Glucose Tolerance. An Open Label Trial. Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
4 Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study Combining HCV and Addiction Treatment of Young Suburban Heroin Users (SHU) That Addresses Barriers to Care Unknown status NCT03364725 Phase 4 Glecaprevir-pibrentasvir
5 Randomized, Multi-Center, Partially Placebo-Controlled Phase IV-Study to Compare Efficacy and Tolerability of 48-Week Combined Therapy With Peginterferon Alfa-2a, Ribavirin and Amantadine Sulphate Versus Placebo in Untreated Patients With Chronic Hepatitis C Virus-Genotype-1-Infection Unknown status NCT00127777 Phase 4 Amantadine sulphate (in addition to standard treatment)
6 Pilot Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2) Unknown status NCT02768545 Phase 4 Ezetimibe
7 Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant Unknown status NCT03359746 Phase 4 Grazoprevir/Elbasvir
8 Effect Of Interferon-Free Direct Acting Antiviral Agents For Treatment Of Hepatitis C Virus Patients On The Normal Kidney Unknown status NCT03296930 Phase 4 Sofosbuvir 400 MG Oral Tablet,;Ombitasvir/paritaprevir/ritonavir
9 Direct Observed Therapy With Ledipasvir/Sofosbuvir in Treatment-naïve Patients With Chronic Genotype 1 HCV (Hepatitis C Virus) Infection Receiving Opiate Substitution Therapy Unknown status NCT02638233 Phase 4 Sofosbuvir 400mg / Ledipasvir 90 mg (FDC)
10 Efficacy and Safety of a Hansenula-derived Pegylated Interferon α2a (Reiferon Retard®) in Treatment of Patients With Chronic Hepatitis C Virus Infection: A National Multi-center Phase IV Open Label Non-Randomized Trial Unknown status NCT01649245 Phase 4 Reiferon retard
11 Efficacy of Pentoxyfylline Addition to a Treatment Scheme Based on Interferon Alpha and Ribavirin on Hepatitis C Virus Coinfected HIV Patients, Considering Interleukin 28B Polymorphism rs12979860 Unknown status NCT02008214 Phase 4 Pentoxifylline;Placebo
12 Generic Velpatasvir Plus Sofosbuvir With or Without Ribavirin for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Completed NCT03250910 Phase 4 Sofosbuvir and Velpatasvir;Ribavirin
13 A Study of the Antiviral Activity of Metformin as an Anti-Hepatitis C Virus Agent in Patients With Chronic Hepatitis C Virus Infection Completed NCT02972723 Phase 4 Metformin
14 A Proof of Concept Study of Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant Completed NCT02945150 Phase 4 elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination)
15 Phase IV Study of Long Term Peg-Intron for Patients Who Have Failed to Respond to Rebetron/Interferon With Advanced Fibrosis and Cirrhosis Secondary to Hepatitis C- The Copilot Trial Completed NCT00179413 Phase 4 PEG -Intron;Colchicine
16 A Multicenter Study Evaluating the Efficacy and Safety of 12 Weeks Versus 24 Weeks Peginterferon Alfa-2a 40KD Combination Therapy With Ribavirin in Interferon Naïve Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Completed NCT00143000 Phase 4 Peginterferon alfa-2a 40KD and Ribavirin
17 Improvement of the Surveillance and Control of Liver Disease and Complication Due to Chronic Hepatitis C: Project A) Antiviral Drugs Use, Efficacy, Safety and Costs; Project B) Kinetics of Virological Response. Completed NCT01195181 Phase 4 peginterferon plus ribavirin
18 Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection Completed NCT01097395 Phase 4 ribavirin
19 A Multi-Site, Open-Label, Partially-Randomized Trial of the Efficacy and Safety of Fixed Dose Elbasvir/Grazoprevir (EBR/GZR) Based Regimens in French Subjects With Chronic Hepatitis C Virus (HCV) Genotype 4 Infection Completed NCT03111108 Phase 4 EBR/GZR (50 mg/100 mg) FDC
20 "Pharmacoepidemiological Evaluation of Autophagy Inhibition in Treatment of HCV Patients Resistant to Standard Therapy. Pilot Study" Completed NCT02058173 Phase 4 150 mg/daily chloroquine compare to placebo for 12 week;Chloroquine;placebo
21 Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4 Completed NCT01686789 Phase 4 Pegylated interferon alpha-2a
22 A Phase 4, Multicenter, Open Label Study to Investigate the Efficacy and Safety of an All Oral Combination of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis VALOR-HCV: Veterans Affairs alL Oral Regimen of SOF+RBV in GT2 HCV Completed NCT02128542 Phase 4 Sofosbuvir;RBV
23 TEN Switch - An Observational Phase IV Study to Evaluate the Safety and Efficacy of Substituting Tenofovir for Didanosine in Virologically Controlled HIV-infected Patients Co-infected With Hepatitis C Virus. Completed NCT00358696 Phase 4 tenofovir
24 Treatment of Acute Hepatitis C Virus Infection in Injection Drug Users With Pegylated Interferon for 24 Weeks Completed NCT00194480 Phase 4 Pegylated Interferon
25 A Phase IV Open-label, Multicentre, International Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir ±Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection and Recent Injection Drug Use or Receiving Opioid Substitution Therapy Completed NCT02498015 Phase 4 "3D" regimen;"3D" regimen with ribavirin
26 Efficacy and Safety Study of Sofosbuvir Containing Regimens in Subjects With Chronic Hepatitis C Virus Genotype 2 Infection Completed NCT02482077 Phase 4 SOF+RBV;SOF+DCV;LDV/SOF
27 Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Genotype 1-infected Patients in Taiwan Completed NCT00495131 Phase 4 Pegylated interferon alfa-2a plus ribavirin;Pegylated interferon alfa-2a plus ribavirin
28 A Prospective, Single-center, Open-label, Pilot Study to Investigate the Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients. Completed NCT01469884 Phase 4 Everolimus;Cyclosporine;Tacrolimus
29 Randomized Study on the Efficacy and Safety of Pegylated Interferon and Ribavirin in Hepatitis C Virus Infection After Liver Transplantation Completed NCT00383864 Phase 4 Pegylated interferon and ribavirin
30 Randomized, Controlled, Open Label, Pilot Study to Evaluate Fosamprenavir Activity on Genotype 1 Hepatitis C Virus (HCV) Infection Evolution in Human Immunodeficiency Virus (HIV) Co-infected Subjects With Antiretroviral Treatment Including Fosamprenavir Completed NCT01222611 Phase 4 Fosamprenavir
31 Pegylated Interferon Alfa-2a Plus Ribavirin for Patients With Chronic Hepatitis c Virus on Opioid Pharmacotherapy: Virological and Psychological Outcomes Completed NCT01120795 Phase 4 Pegylated interferon and ribavirin;Pegylated interferon and ribavirin
32 An Open-Label, Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus (HCV) Infection Genotype 2K/1B- NINJA Study Completed NCT03050905 Phase 4 VEKIRAX;EXVIERA
33 A Phase Iv Single-Arm Open-Label Non-Randomized Study To Evaluate The Safety And Pharmacokinetics Of Nelfinavir (Viracept, A430) 1250mg Twice Daily (250mg Or 625mg Forms) With Lamivudine/Zidovudine (Combivir) Background Therapy In Hiv/Hepatitis C Virus (Hcv) Co-Infected Subjects With Hepatic Dysfunction. Completed NCT00141284 Phase 4 nelfinavir 1,250 mg twice daily;Zidovudine 300 mg twice daily;Lamivudine 150 mg twice daily
34 A Randomized Trial Comparing a Short Course Versus Standard Treatment in Patients With Chronic Hepatitis C Virus Infection Completed NCT00502970 Phase 4 16 weeks Interferon Tiw with Ribavirin;24 weeks Interferon
35 Evaluation of Liver Fibrosis by Serum Hyalornic Acid Measurement in β-Thalassemic Children Infected With Hepatitis C Virus Before and After Direct-Acting Antiviral Therapy Completed NCT03961828 Phase 4 Ledipasvir 90 MG / Sofosbuvir 400 MG [Harvoni]
36 Treatment of Acute Hepatitis C Virus in HIV Co-Infection Completed NCT00845676 Phase 4 Pegylated interferon alfa-2a + Ribavirin
37 Analysis of Gene Expression of PBMC in the Hepatitis C Virus Genotype 1b-infected Patients During Peg-interferon-α Plus Ribavirin Combination Therapy Completed NCT00680173 Phase 4 pegylated interferon alpha 2a and plus ribavirin
38 A Pilot Study to Assess the Feasibility of Hepatitis C Virus (HCV) Treatment as Prevention With Interferon-free Direct Acting Antivirals (DAAs) in the Prison Setting Completed NCT02064049 Phase 4 Sofosbuvir/velpatasvir
39 Treatment of Recently Acquired Hepatitis C Virus Infection Completed NCT01336010 Phase 4 Peginterferon alfa-2a;Ribavirin
40 Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir for Treatment-Naive and Treatment-Experienced Non-Cirrhotic Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis Completed NCT02874066 Phase 4 PTV/r/OBV/DSV
41 Elbasvir/Grazoprevir for Treatment-naive and Treatment-experienced Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis Completed NCT03420300 Phase 4 EBR/GZR
42 Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study Completed NCT02220868 Phase 4 Sofosbuvir, Ribavirin, and Stribild
43 Randomized Clinical Trial to Assess the Effectiveness of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 1 (TNT-1 Study) Completed NCT02624063 Phase 4 Daclatasvir + Sofosbuvir;Simeprevir + Sofosbuvir
44 A Pilot Study to Evaluate Anti-Hepatitis C Virus Effect of Maraviroc in Patients Co-infected With Human Immunodeficiency Virus (HIV) and Hepatitis C Completed NCT02881762 Phase 4 Maraviroc
45 A Phase IV, Multisite Study of the Treatment of Chronic Hepatitis C Virus Infection Genotype 1 in a Real World Large Health Maintenance Organization: An Evaluation of Real World Sustained Virological Response and Patient Reported Outcomes Completed NCT02461745 Phase 4 ombitasvir, paritaprevir/r, dasabuvir + ribavirin;ombitasvir, paritaprevir/r, dasabuvir
46 Evaluation of the Benefit of Antithymocyte Induction Therapy on Hepatic Fibrosis in de Novo Hepatitis C Virus Liver Transplant Patients. Completed NCT00538265 Phase 4 tacrolimus;tacrolimus, ATG;ATG+mycophénolate mofétil+tacrolimus
47 Management of Hepatitis C Virus (HCV) Infection in Pregnant Women With Opioid Use Disorder (OUD): the Potential of an Integrated Medical Home Model: Phase IV Trial of Sofosbuvir/Velpatasvir (SOF/VEL) in Postpartum Women With Chronic HCV Recruiting NCT03057847 Phase 4 Sofosbuvir/Velpatasvir
48 the Prevalence of Acute Kidney Injury in Patients With Chronic Hepatitis c Virus Receiving Sofuspovir Containing Direct Acting Antiviral Therapy Recruiting NCT04267458 Phase 4
49 A Phase IV, Single Arm, Open-Label Study to Determine the Efficacy and Safety of Ledipasvir/Sofosbuvir (LDV/SOF) in Treatment-Naive Alcoholic Subjects With Chronic Genotype 1 Hepatitis C Infection Active, not recruiting NCT02759861 Phase 4 harvoni
50 Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment: A Pilot Project Active, not recruiting NCT02460133 Phase 4 Paritaprevir;Ritonavir;Dasabuvir;Ombitasvir;Ribavirin

Search NIH Clinical Center for Hepatitis C Virus

Genetic Tests for Hepatitis C Virus

Genetic tests related to Hepatitis C Virus:

# Genetic test Affiliating Genes
1 Susceptibility to Hepatitis C Virus 29 CCR5 IFNG IFNL3 PTPRC
2 Hepatitis C Virus Infection, Response to Therapy of 29

Anatomical Context for Hepatitis C Virus

MalaCards organs/tissues related to Hepatitis C Virus:

40
Liver, Kidney, T Cells, Bone, Bone Marrow, Thyroid, B Cells

Publications for Hepatitis C Virus

Articles related to Hepatitis C Virus:

(show top 50) (show all 30049)
# Title Authors PMID Year
1
A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. 61 6 57
17215375 2007
2
Altered CD45 expression in C77G carriers influences immune function and outcome of hepatitis C infection. 57 6
16505159 2006
3
The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. 57 6
15863470 2005
4
MCPIP1 suppresses hepatitis C virus replication and negatively regulates virus-induced proinflammatory cytokine responses. 57 61
25225661 2014
5
IPS-1 is essential for type III IFN production by hepatocytes and dendritic cells in response to hepatitis C virus infection. 57 61
24532585 2014
6
A class II phosphoinositide 3-kinase plays an indispensable role in hepatitis C virus replication. 61 57
24055031 2013
7
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. 57 61
23291588 2013
8
Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. 61 57
22231557 2012
9
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. 57 61
21516087 2011
10
Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1. 61 57
20935628 2010
11
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. 57 61
19965718 2010
12
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. 61 57
19759533 2009
13
A genome-wide genetic screen for host factors required for hepatitis C virus propagation. 57 61
19717417 2009
14
Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus. 57 61
17804490 2007
15
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. 61 57
17325668 2007
16
Apolipoprotein epsilon3 allele is associated with persistent hepatitis C virus infection. 61 57
16299033 2006
17
Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. 61 57
16141076 2005
18
Unravelling hepatitis C virus replication from genome to function. 61 57
16107832 2005
19
Unscrambling hepatitis C virus-host interactions. 61 57
16107831 2005
20
Adaptive immune responses in acute and chronic hepatitis C virus infection. 61 57
16107834 2005
21
Evasion of intracellular host defence by hepatitis C virus. 61 57
16107833 2005
22
Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. 61 57
15893726 2005
23
HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. 57 61
15297676 2004
24
Pathophysiology of hepatitis C virus infection and related liver disease. 61 57
15036326 2004
25
Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. 57 61
12702807 2003
26
L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. 57 61
12676990 2003
27
Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. 57 61
12634366 2003
28
The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. 61 57
12356718 2002
29
Subversion of cell signaling pathways by hepatitis C virus nonstructural 5A protein via interaction with Grb2 and P85 phosphatidylinositol 3-kinase. 61 57
12186904 2002
30
Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. 57 61
11781363 2002
31
Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. 61 57
11781364 2002
32
Identification of eIF2Bgamma and eIF2gamma as cofactors of hepatitis C virus internal ribosome entry site-mediated translation using a functional genomics approach. 57 61
10900014 2000
33
Hepatitis C virus core protein-induced loss of LZIP function correlates with cellular transformation. 61 57
10675342 2000
34
Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. 61 57
10609818 1999
35
Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. 61 57
10535997 1999
36
NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. 61 57
10318918 1999
37
Binding of hepatitis C virus to CD81. 57 61
9794763 1998
38
Interferon-inducible protein SCOTIN interferes with HCV replication through the autolysosomal degradation of NS5A. 57
26868272 2016
39
RACK1 controls IRES-mediated translation of viruses. 57
25416947 2014
40
IFN-λ receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-λ3 genotype and with nonresponsiveness to IFN-α therapies. 57
24752298 2014
41
IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. 57
23712427 2013
42
A disease-associated polymorphism alters splicing of the human CD45 phosphatase gene by disrupting combinatorial repression by heterogeneous nuclear ribonucleoproteins (hnRNPs). 6
21507955 2011
43
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. 57
20547162 2010
44
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. 57
20173735 2010
45
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. 57
19749758 2009
46
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. 57
19749757 2009
47
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. 57
19684573 2009
48
An investigation of the C77G and C772T variations within the human protein tyrosine phosphatase receptor type C gene for association with multiple sclerosis in an Australian population. 6
19111528 2009
49
Shared and distinct genetic variants in type 1 diabetes and celiac disease. 6
19073967 2008
50
Interaction between RANTES promoter variant and CCR5Delta32 favors recovery from hepatitis B. 6
19017985 2008

Variations for Hepatitis C Virus

ClinVar genetic disease variations for Hepatitis C Virus:

6 (show all 11)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CCR5 , CCR5AS NM_000579.3(CCR5):c.554_585del (p.Ser185fs) Deletion protective 8184 rs333 GRCh37: 3:46414944-46414975
GRCh38: 3:46373453-46373484
2 IFNG NM_000619.2(IFNG):c.-893C>G SNV drug response 14725 rs2069707 GRCh37: 12:68554288-68554288
GRCh38: 12:68160508-68160508
3 PTPRC PTPRC, 77C-G SNV risk factor 14456 GRCh37:
GRCh38:
4 KRT8 NM_002273.4(KRT8):c.160T>C (p.Tyr54His) SNV Uncertain significance 14631 rs57749775 GRCh37: 12:53298606-53298606
GRCh38: 12:52904822-52904822
5 KRT8 NM_002273.4(KRT8):c.187A>G (p.Ile63Val) SNV Benign 66533 rs59536457 GRCh37: 12:53298579-53298579
GRCh38: 12:52904795-52904795
6 LOC106096416 , KRT18 NM_000224.3(KRT18):c.1230C>G (p.Thr410=) SNV not provided 56165 rs386834225 GRCh37: 12:53346563-53346563
GRCh38: 12:52952779-52952779
7 LOC106096416 , KRT18 , KRT8 NM_000224.3(KRT18):c.282C>T (p.Tyr94=) SNV not provided 56166 rs386834224 GRCh37: 12:53343239-53343239
GRCh38: 12:52949455-52949455
8 LOC106096416 , KRT18 , KRT8 NM_000224.3(KRT18):c.134G>C (p.Arg45Pro) SNV not provided 56167 rs200221269 GRCh37: 12:53343091-53343091
GRCh38: 12:52949307-52949307
9 KRT8 NM_002273.4(KRT8):c.1033G>T (p.Ala345Ser) SNV not provided 56168 rs386834221 GRCh37: 12:53292632-53292632
GRCh38: 12:52898848-52898848
10 KRT8 NM_002273.4(KRT8):c.1340C>T (p.Ala447Val) SNV not provided 56169 rs386834223 GRCh37: 12:53291324-53291324
GRCh38: 12:52897540-52897540
11 KRT8 NM_002273.4(KRT8):c.1412G>A (p.Gly471Glu) SNV not provided 56170 rs386834222 GRCh37: 12:53291252-53291252
GRCh38: 12:52897468-52897468

Cosmic variations for Hepatitis C Virus:

9 (show top 50) (show all 15388)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM97724722 ZXDB liver,NS,carcinoma,hepatocellular carcinoma c.1308C>A p.D436E 23:57593356-57593356 6
2 COSM94430614 ZSWIM1 liver,NS,carcinoma,hepatocellular carcinoma c.1399A>C p.S467R 20:45883991-45883991 6
3 COSM94436083 ZSWIM1 liver,NS,carcinoma,hepatocellular carcinoma c.1399A>C p.S467R 20:45883991-45883991 6
4 COSM94063771 ZSCAN20 liver,NS,carcinoma,hepatocellular carcinoma c.2314G>T p.G772W 1:33494658-33494658 6
5 COSM88264637 ZRSR2 liver,NS,carcinoma,hepatocellular carcinoma c.304G>T p.E102* 23:15803788-15803788 6
6 COSM102741209 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.859A>G p.M287V 22:29049340-29049340 6
7 COSM131494492 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.1159A>G p.M387V 22:29049340-29049340 6
8 COSM103081572 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.859A>G p.M287V 22:29049340-29049340 6
9 COSM95977701 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860= 20:49257501-49257501 6
10 COSM102131817 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860= 20:49257501-49257501 6
11 COSM95960776 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860= 20:49257501-49257501 6
12 COSM113317148 ZNF853 liver,NS,carcinoma,hepatocellular carcinoma c.1610G>T p.G537V 7:6622601-6622601 6
13 COSM99592496 ZNF829 liver,NS,carcinoma,hepatocellular carcinoma c.829T>A p.F277I 19:36891962-36891962 6
14 COSM128686611 ZNF829 liver,NS,carcinoma,hepatocellular carcinoma c.1072T>A p.F358I 19:36891962-36891962 6
15 COSM123358576 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.691C>T p.L231= 4:145885684-145885684 6
16 COSM123949383 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.1741C>T p.L581= 4:145885684-145885684 6
17 COSM101741672 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.1741C>T p.L581= 4:145885684-145885684 6
18 COSM86004822 ZNF653 liver,NS,carcinoma,hepatocellular carcinoma c.1553A>C p.H518P 19:11485673-11485673 6
19 COSM98561269 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 6
20 COSM142353152 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 6
21 COSM142221290 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 6
22 COSM99854658 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.156G>A p.V52= 19:52002156-52002156 6
23 COSM139729931 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 6
24 COSM141470046 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 6
25 COSM141819438 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 6
26 COSM145038099 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 6
27 COSM91868668 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.3900G>T p.K1300N 19:30557161-30557161 6
28 COSM91880764 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.2171-78T>G p.? 19:30534769-30534769 6
29 COSM140721836 ZNF521 liver,NS,carcinoma,hepatocellular carcinoma c.2998+205G>A p.? 18:25194955-25194955 6
30 COSM131506983 ZNF521 liver,NS,carcinoma,hepatocellular carcinoma c.3658+205G>A p.? 18:25194955-25194955 6
31 COSM94799980 ZNF521 liver,NS,carcinoma,hepatocellular carcinoma c.3658+205G>A p.? 18:25194955-25194955 6
32 COSM90582798 ZNF518B liver,NS,carcinoma,hepatocellular carcinoma c.1624G>T p.E542* 4:10444705-10444705 6
33 COSM87577038 ZNF462 liver,NS,carcinoma,hepatocellular carcinoma c.6715G>T p.V2239L 9:106974156-106974156 6
34 COSM109096265 ZNF462 liver,NS,carcinoma,hepatocellular carcinoma c.3433G>T p.V1145L 9:106974156-106974156 6
35 COSM104985080 ZNF385B liver,NS,carcinoma,hepatocellular carcinoma c.298+23785G>T p.? 2:179745718-179745718 6
36 COSM104427909 ZNF385B liver,NS,carcinoma,hepatocellular carcinoma c.20G>T p.S7I 2:179745718-179745718 6
37 COSM151538615 ZNF385B liver,NS,carcinoma,hepatocellular carcinoma c.253+23785G>T p.? 2:179745718-179745718 6
38 COSM127708351 ZNF345 liver,NS,carcinoma,hepatocellular carcinoma c.47-856A>T p.? 19:36891962-36891962 6
39 COSM135887725 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1168C>G p.L390V 16:89734008-89734008 6
40 COSM84511025 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1219C>G p.L407V 16:89734008-89734008 6
41 COSM111609487 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1444C>G p.L482V 16:89734008-89734008 6
42 COSM92353291 ZNF26 liver,NS,carcinoma,hepatocellular carcinoma c.1010C>T p.T337I 12:133010889-133010889 6
43 COSM130415812 ZNF26 liver,NS,carcinoma,hepatocellular carcinoma c.950C>T p.T317I 12:133010889-133010889 6
44 COSM88697750 ZNF217 liver,NS,carcinoma,hepatocellular carcinoma c.*194A>T p.? 20:53569094-53569094 6
45 COSM95253159 ZNF217 liver,NS,carcinoma,hepatocellular carcinoma c.*194A>T p.? 20:53569094-53569094 6
46 COSM94505616 ZMYND12 liver,NS,carcinoma,hepatocellular carcinoma c.425-1G>T p.? 1:42440026-42440026 6
47 COSM89943752 ZMYM4 liver,NS,carcinoma,hepatocellular carcinoma c.86-8201G>T p.? 1:35350724-35350724 6
48 COSM101398456 ZIC2 liver,NS,carcinoma,hepatocellular carcinoma c.-18C>T p.? 13:99982047-99982047 6
49 COSM113521587 ZGPAT liver,NS,carcinoma,hepatocellular carcinoma c.*197C>A p.? 20:63736116-63736116 6
50 COSM94679661 ZGPAT liver,NS,carcinoma,hepatocellular carcinoma c.*197C>A p.? 20:63736116-63736116 6

Expression for Hepatitis C Virus

LifeMap Discovery
Genes differentially expressed in tissues of Hepatitis C Virus patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CXCL10 C-X-C motif chemokine ligand 10 Liver + 4.26 0.000
2 CXCL11 C-X-C motif chemokine ligand 11 Liver + 3.57 0.000
3 LINC02532 long intergenic non-protein coding RNA 2532 Liver - 3.21 0.000
4 CXCL9 C-X-C motif chemokine ligand 9 Liver + 3.07 0.000
Search GEO for disease gene expression data for Hepatitis C Virus.

Pathways for Hepatitis C Virus

Pathways related to Hepatitis C Virus according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.1 SCARB1 IFNG EIF2AK2 DDX3X CLDN9 CLDN6

GO Terms for Hepatitis C Virus

Cellular components related to Hepatitis C Virus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell periphery GO:0071944 8.8 PTPRC KRT8 KRT18

Biological processes related to Hepatitis C Virus according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.92 IFNL4 IFNL3 EIF2AK2 DDX3X CLEC4M
2 tumor necrosis factor-mediated signaling pathway GO:0033209 9.74 PSMA7 KRT8 KRT18
3 response to virus GO:0009615 9.73 IFNG EIF2AK2 DDX3X
4 calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules GO:0016338 9.58 CLDN9 CLDN6
5 reverse cholesterol transport GO:0043691 9.55 SCARB1 APOE
6 high-density lipoprotein particle remodeling GO:0034375 9.54 SCARB1 APOE
7 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.51 IFNG APOE
8 extrinsic apoptotic signaling pathway GO:0097191 9.5 KRT8 KRT18 IFNG
9 positive regulation of immune response GO:0050778 9.49 IFNL4 IFNL3
10 virion assembly GO:0019068 9.48 TBC1D20 APOE
11 hepatocyte apoptotic process GO:0097284 9.46 KRT8 KRT18
12 viral entry into host cell GO:0046718 9.46 SCARB1 CLEC4M CLDN9 CLDN6
13 cholesterol catabolic process GO:0006707 9.43 SCARB1 APOE
14 JAK-STAT cascade GO:0007259 9.43 IFNL4 IFNL3 IFNG
15 regulation of phagocytosis GO:0050764 9.4 SCARB1 PTPRC
16 viral process GO:0016032 9.4 TBC1D20 SCARB1 PTPRC PSMA7 KRT8 KRT18
17 high-density lipoprotein particle clearance GO:0034384 9.37 SCARB1 APOE
18 defense response to virus GO:0051607 9.35 PTPRC IFNL4 IFNL3 IFNG EIF2AK2

Molecular functions related to Hepatitis C Virus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural molecule activity GO:0005198 9.26 KRT18 CLDN9 CLDN6 APOE
2 heparan sulfate proteoglycan binding GO:0043395 9.16 PTPRC APOE
3 virus receptor activity GO:0001618 9.02 SCARB1 CLEC4M CLDN9 CLDN6 CCR5

Sources for Hepatitis C Virus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....